TrialDrug and alcohol dependence2008

A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Elmer Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.